As one of the most common endocrine disorders, thyroid diseases can be classified into different categories, such as hypothyroidism, hyperthyroidism, thyroid nodule, etc., through the concentration detection of main thyroid hormones triiodothyronine (T3) and thyroxine (T4) in the form of either total or free, as well as TSH in the serum.
So, analytical performance of thyroid hormones immunoassays is worthy of more attention. Total error (TE), introduced by Westgard, 6 was composed of systematic error and random error. The TE model can be expressed as equation: TE=average bias+Z×imprecision (Z defines the level of confidence, usually 1.65). 7 TE, bias, and imprecision (expressed as CV or SD) were three important indicators used to reflect analytical accuracy, trueness, and precision. Using immunoassays with better precision (smaller CV) is one of important aspects to decrease TE and improve accuracy of diagnosis and treatment.
Internal quality control (IQC), as an effective tool to discover detection errors in the analytical phase, plays a key role in improving precision level of clinical laboratories. 8, 9 Through collecting 2011-
IQC results in the national External Quality Assessment (EQA)
programs and assessing percentages of laboratories meeting five different performance specifications of precision, this study was to make a conclusion for FT3, TT3, FT4, TT4, and TSH whether the IQC practice had changed and whether the precision performance of Chinese clinical laboratories had made great progress, also help laboratories select the most appropriate allowable imprecision specification and raise precision level.
| MATERIALS AND METHODS

| Subjects
Clinical laboratories came from all over the China which continuously participated in the national EQA programs of FT3, TT3, FT4, TT4, and TSH organized by National Center for Clinical Laboratories of China (CNCCL), the official Proficiency Testing provider in China, and submitted their IQC information from 2011 to 2016.
| Study design
In the annual EQA cycle of each analyte in China, when participant lab- CVs were less than an evaluation criterion, the precision of this laboratory was considered to be acceptable in the performance request of this evaluation criterion. In each group divided by year and manufacturers of measurement systems (referring to closed systems whose reagent and calibrator matched with the instrument deriving from the same manufacture), etc., the pass rates were defined as the ratio of "the number of laboratories with acceptable precision performance"
to "the total number of laboratories in each group". In the subsequent section of this article, five allowable imprecision specifications were respectively abbreviated as minimum specification, desirable specification, optimum specification, 1/3TEa specification, and 1/4TEa specification.
T A B L E 1 Allowable imprecision specifications (%) for each analyte
| Analytical performance specifications for precision
To evaluate precision performance of clinical laboratories, the current CVs should be compared with five objective allowable imprecision specifications ( Table 1 ).The former three respectively were minimum, desirable, and optimum levels of allowable imprecision specifications based on biological variation, which should be calculated according to the formula defined as 0.75CV I , 0.50CV I , and 0.25CV I . CV I , the withinsubject biological variation, was provided by Ricos and updated by
Westgard on the website (http://www.westgard.com/biodatabase1. htm). The remaining two, 1/3 TEa and 1/4 TEa, were allowable imprecision specifications recommended by CLIA' 88.
| Statistical analysis
The distributions of current CVs were presented as several percentiles including 5th, 25th, 50th (median), 75th, and 95th percentiles. ) test was used to compare pass rates and constituent ratios between or among different years or groups. The differences, between or among comparators, were considered to be statistically significant when the P-value is ≤.05. 
| RESULTS
In
| Imprecision analysis
For five analytes, the distribution of current CVs of level 1 was shown in Figure 2 . For FT3, the current CVs among 6 years were different significantly (P=.027). 
| Imprecision analysis by measurement systems
Immunoassays of five thyroid hormones were conducted by four mainstream measurement systems Abbott, Beckman, Roche and Siemens in China. The constituent ratios of these four mainstream measurement systems had not significantly changed with time (all P>.05). For five analytes, the constituent ratios of Roche in 6 years were the highest (about 40%), followed by Siemens (about 25%), Beckman (about 16%-18%), and Abbott (about 10%) in sequence. The proportions of other measurement systems were the lowest (about 7%-8%) and also changed without significant difference (P>.05).
The current CVs of four mainstream measurement systems were further analyzed and shown in Table S1 (in supplementary materials).
In general, except for FT3, the current CVs of Roche both were below Additionally, the change of IQC practice can also affect the measurement quality. Half of the participant laboratories did not realize the importance of using multiple levels of control materials. Besides, the measurement range of each level was also not specified, so there may be an overlap between two levels. 8 Second, most of research subjects (about 80.0%) were in tertiary hospitals which can be considered as representatives of laboratories with better analytical performance and focus more on their quality management than those which did not participant. So, results of this study cannot reflect the overall precision level of these analytes in China. Third, this study only gave a data report without advice on how to improve unsatisfied precision performance. It is high time that we should conduct further precision study including different hospital types and provide guidance to participant laboratories how to improve precision performance according to CVs and IQC practice. In addition, comparing with IQC studies in western countries, 10,11 CNCCL should enrich Chinese IQC surveys to not only estimate within-laboratory imprecision but also assess between-laboratory and within-method imprecision. Meanwhile, the trend of standardization and harmonization for thyroid hormones immunoassays in abroad 17, 18 is also the direction of development for Chinese EQA schemes.
It is meaningful that CNCCL collect long-term IQC data for statistical analysis. With the change of IQC practice in 6 years, only FT3 had the precision performance improved with decreasing current CVs and increasing pass rates. However, in general, unsatisfying current CVs and pass rates illustrated more efforts should be made to improve precision performance of thyroid hormones immunoassays.
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